Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
kneat.com ( (TSE:KSI) ) just unveiled an update.
Kneat.com, Inc., a specialist in digitizing validation and quality workflows for life sciences, has built a reputation as a trusted system of record in highly regulated settings. Its no-code, configurable platform emphasizes audit-ready data, deep regulatory alignment, and strong customer support, helping large pharmaceutical customers modernize compliance and quality operations amid growing adoption of AI.
The company’s 2025 shareholder letter reports 33% software revenue growth, record new customer additions, and Annual Recurring Revenue surpassing $74 million, supported by a 115% Net Revenue Retention rate despite some deferred expansions and churn among non-strategic accounts. Management positions AI as a growth catalyst rather than a threat, highlighting new GxP-aligned AI tools and a roadmap for further automation, while strong satisfaction scores and market share gains underscore Kneat’s reinforced competitive moat and expansion potential heading into 2026.
The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$5.50 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.
Spark’s Take on TSE:KSI Stock
According to Spark, TipRanks’ AI Analyst, TSE:KSI is a Neutral.
Kneat.com’s overall stock score reflects strong SaaS revenue growth and high customer satisfaction, which are offset by profitability challenges and cash flow constraints. The technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio. Strategic investments in R&D are promising, but increased operating expenses and macroeconomic headwinds pose risks.
To see Spark’s full report on TSE:KSI stock, click here.
More about kneat.com
Kneat.com, Inc., based in Limerick, Ireland, provides enterprise software that digitizes and automates validation and quality processes for highly regulated life sciences manufacturers. Its platform serves many of the world’s largest pharmaceutical companies, including eight of the top ten, focusing on compliance, traceability, and data integrity in GxP-aligned environments.
Average Trading Volume: 145,766
Technical Sentiment Signal: Sell
Current Market Cap: C$394.6M
For a thorough assessment of KSI stock, go to TipRanks’ Stock Analysis page.